[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367667-105":59,"doc-detail-367667-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","microfluidic-liquid-biopsy-nano-plasmonic-label-free-detection-of-extracellular-vesicles-review","Microfluidic Liquid Biopsy - Nano-Plasmonic Label-Free Detection of Extracellular Vesicles - Review","","Cancer diagnosis needs alternative techniques enabling early detection with non-invasive or minimally invasive workflows. Tissue biopsy is reliable but highly traumatic and limited by lesion size, single-sample capture, and inability to reflect treatment response in time. Liquid biopsy mitigates invasiveness by analyzing cancer biomarkers in blood or urine, yet early-stage disease often produces very low levels, challenging sensitivity. Extracellular vesicles improve biomarker relevance, while label-free plasmonic biosensors and Raman approaches help overcome low sensitivity, EV heterogeneity, and purification difficulty, supporting rapid, cost-effective testing for improved outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/microfluidic-liquid-biopsy-nano-plasmonic-label-free-detection-of-extracellular-vesicles-review/367667/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/microfluidic-liquid-biopsy-nano-plasmonic-label-free-detection-of-extracellular-vesicles-review/367667.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is early cancer diagnosis difficult with traditional tissue biopsy?","Question",{"text":113,"@type":114},"Early-stage lesions are often small, and tissue biopsy is invasive and traumatic. It also samples only one tumor region and may not represent tumor heterogeneity or provide timely information for monitoring treatment response.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is liquid biopsy and what biomarkers does it analyze?",{"text":118,"@type":114},"Liquid biopsy is a diagnostic procedure that tests circulating cancer biomarkers in body fluids such as blood and urine. It can include circulating tumor cells, circulating nucleic acids, tumor-educated platelets, and extracellular vesicles.",{"name":120,"@type":111,"acceptedAnswer":121},"What challenges affect EV-based liquid biopsy and how do label-free methods help?",{"text":122,"@type":114},"EV-based approaches face low sensitivity, EV subtype heterogeneity, and difficulty isolating pure populations. Label-free strategies such as plasmonic biosensors and Raman spectroscopy enable direct analysis without labeled markers, improving accuracy while reducing complexity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367667,1790231483,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review  \nMicrofluidic Liquid Biopsy Minimally Invasive Cancer Diagnosis by Nano-Plasmonic Label-Free Detection of Extracellular Vesicles: Review  \nKeshava Praveena Neriya Hegade , Rama B. Bhat and Muthukumaran Packirisamy *  \nAcademic Editor: Steven Fiering  \nReceived: 29 May 2025  \nRevised: 25 June 2025  \nAccepted: 28 June 2025  \nPublished: 1 July 2025  \nCitation: Neriya Hegade, K.P.; Bhat, R.B.; Packirisamy, M. Microfluidic Liquid Biopsy Minimally Invasive Cancer Diagnosis by Nano-Plasmonic Label-Free Detection of Extracellular Vesicles: Review. Int. J. Mol. Sci. 2025, 26, 6352. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26136352  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nOptical Bio-Microsystems Laboratory, Department of Mechanical and Industrial Engineering, Concordia University, Montreal, QC H3G 1M8, Canada; [keshavapraveena.neriyahegade@mail.concordia.ca](keshavapraveena.neriyahegade@mail.concordia.ca) (K.P.N.H.)  \n* [Correspondence: pmuthu@alcor.concordia.ca](Correspondence: pmuthu@alcor.concordia.ca); Tel.: +1-514-848-2424 (ext. 7973); Fax: +1-514-848-3175  \nAbstract  \nCancer diagnosis requires alternative techniques that allow for early, non-invasive, or minimally invasive identification. Traditional methods, like tissue biopsies, are highly invasive and can be traumatic for patients. Liquid biopsy, a less invasive option, detects cancer biomarkers in body fluids such as blood and urine. However, early-stage cancer often presents low biomarker levels, making sensitivity a challenge for integrating liquid biopsy into early diagnosis. Recent studies revealed that extracellular vesicles (EVs) secreted by cells are apt markers for liquid biopsy. Detecting extracellular vesicles (EVs) for liquid biopsy faces challenges like low sensitivity, EV subtype heterogeneity, and difficulty isolating pure populations. Label-free methods, such as plasmonic biosensors and Raman spectroscopy, offer potential solutions by enabling direct analysis without markers, improving accuracy, and reducing complexity. This review paper discusses current challenges in EV-based liquid biopsy for cancer diagnosis and prognosis. It addresses the effective use of microfluidics and nano-plasmonic approaches to address these challenges. Enhancing label-free EV detection in liquid biopsy could revolutionize early cancer diagnosis by offering non-invasive, cost-effective, and rapid testing. This could improve patient outcomes through personalized treatment and ease the burden on healthcare systems.  \nKeywords: extracellular vesicles; exosomes; liquid biopsy; cancer prognosis; cancer diagnosis; minimally invasive diagnosis; microfluidics; nano-plasmonic detection  \n1. Introduction  \nCancer diagnosis typically involves a combination of radiographic imaging, surgical procedures, and chemotherapy treatments. Radiography procedures such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), and Endoscopic Ultrasound (EUS) are limited by the size of the lesion in the early-stage cancer. Tissue biopsy has been a reliable diagnostic technique for detecting cancer. In this method, a part of the “suspected tumor”(lesion) from the patient is surgically removed and studied for the presence of an oncogene. Hence, tissue biopsy can potentially be highly invasive based on the location of the lesion. Surgery presents a traumatic experience for the patient at the pre-diagnostic stage. Tissue biopsies capture a single sample of tumor tissue, thus ignoring the tumor heterogeneity, making this technique inadequate for frequent repetition. Furthermore, tissue biopsy cannot reflect the response to the cancer treatment because it ne","cbCaifbV8MWUhWcL","https://ap.wps.com/l/cbCaifbV8MWUhWcL","pdf",3419287,37,"English","# Introduction\n## Cancer diagnosis: limitations of traditional tissue biopsy\n## Liquid biopsy overview and circulating biomarkers\n## Extracellular vesicles as liquid biopsy markers\n## Challenges and promise of label-free nano-plasmonic detection","[{\"question\":\"Why is early cancer diagnosis difficult with traditional tissue biopsy?\",\"answer\":\"Early-stage lesions are often small, and tissue biopsy is invasive and traumatic. It also samples only one tumor region and may not represent tumor heterogeneity or provide timely information for monitoring treatment response.\"},{\"question\":\"What is liquid biopsy and what biomarkers does it analyze?\",\"answer\":\"Liquid biopsy is a diagnostic procedure that tests circulating cancer biomarkers in body fluids such as blood and urine. It can include circulating tumor cells, circulating nucleic acids, tumor-educated platelets, and extracellular vesicles.\"},{\"question\":\"What challenges affect EV-based liquid biopsy and how do label-free methods help?\",\"answer\":\"EV-based approaches face low sensitivity, EV subtype heterogeneity, and difficulty isolating pure populations. Label-free strategies such as plasmonic biosensors and Raman spectroscopy enable direct analysis without labeled markers, improving accuracy while reducing complexity.\"}]","Microfluidic Liquid Biopsy - Nano-Plasmonic Label-Free Detection of Extracellular Vesicles - Review | PDF",1790171877,93,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/873a89eb092691e49a532c6951492660.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10118316d5ebf0684bd54955ca2c0fb9.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8fe5bcdcfd0ebf6a1b0e811c8f67f66.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/deffce27b2fcbb7926a8e59bd71d0d19.webp",980,1385]